Welcome to our dedicated page for Dyne Therapeutics news (Ticker: DYN), a resource for investors and traders seeking the latest updates and insights on Dyne Therapeutics stock.
Dyne Therapeutics, Inc. develops investigational therapies for genetically driven neuromuscular diseases using its FORCE platform, which is designed to deliver payloads to muscle tissue and the central nervous system. Company news centers on clinical programs in Duchenne muscular dystrophy and myotonic dystrophy type 1, including z-rostudirsen, z-basivarsen, the DELIVER, ACHIEVE and HARMONIA studies, and preclinical work in additional neuromuscular diseases.
Recurring updates include clinical data presentations, FDA interactions and designations, financial results, cash-resource commentary, medical-conference abstracts, access-related research, investor conference participation and Nasdaq inducement equity grants.
Dyne Therapeutics (Nasdaq: DYN) closed its previously announced upsized underwritten public offering of 21,045,000 shares of common stock at $20.50 per share. This total includes 2,745,000 shares sold upon the underwriters’ full exercise of their option to purchase additional shares.
According to Dyne Therapeutics, the offering generated gross proceeds of approximately $431.4 million before underwriting discounts, commissions and expenses. All shares were issued and sold by the company under an automatically effective Form S-3 shelf registration, with Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital, Raymond James and Jones managing the deal.
Dyne Therapeutics (Nasdaq:DYN) has priced an upsized underwritten public offering of 18,300,000 shares of common stock at $20.50 per share, for expected gross proceeds of approximately $375.15 million before fees and expenses. All shares are being sold by Dyne.
The offering is expected to close on or about July 23, 2026, subject to customary conditions. Dyne has granted underwriters a 30-day option to purchase up to an additional 2,745,000 shares. Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital, Raymond James and Jones are managing the transaction.
Dyne Therapeutics (Nasdaq: DYN) has commenced an underwritten public offering of $300 million of its common stock. The company also plans to grant underwriters a 30‑day option to purchase up to an additional $45 million of common shares.
All shares in the proposed offering will be sold by Dyne. Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital and Raymond James are acting as joint book‑running managers, with Jones as lead manager. The transaction is being conducted under an automatically effective Form S‑3 shelf registration filed on March 5, 2024, and remains subject to market and other conditions, with final terms to be disclosed in a forthcoming final prospectus supplement filed with the SEC.
Dyne Therapeutics (Nasdaq: DYN) reported that the U.S. FDA has accepted for review its Biologics License Application (BLA) for zeleciment rostudirsen (z-rostudirsen, DYNE-251) to treat Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. The BLA was granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) target action date of January 21, 2027, and is submitted under the Accelerated Approval pathway using dystrophin as a surrogate endpoint.
According to Dyne, in the registrational expansion cohort of the DELIVER trial, dosing z-rostudirsen once every four weeks led to a robust and statistically significant increase in dystrophin production, functional improvement across multiple clinical endpoints, and a favorable safety profile. Assuming approval on the anticipated timeline, Dyne continues to plan for a potential U.S. launch in Q1 2027. The company is also advancing four additional candidates targeting DMD amenable to skipping exons 53, 45, 44 and 55.
Dyne Therapeutics (Nasdaq: DYN) appointed Barry Greene to its Board of Directors, adding more than 30 years of biopharmaceutical leadership experience.
Greene has held senior roles at Sage Therapeutics, Alnylam Pharmaceuticals and Millennium Pharmaceuticals, with a background in rare diseases, neuroscience, oncology and multiple therapy launches.
The appointment aligns with Dyne’s plans to evolve from a clinical-stage company toward potential product approvals, launches and future revenue generation in genetically driven neuromuscular diseases.
Dyne Therapeutics (Nasdaq:DYN) granted inducement equity awards to six new employees under Nasdaq Listing Rule 5635(c)(4). Awards include non-statutory stock options for up to 126,000 shares and 40,100 restricted stock units, granted under Dyne’s 2024 Inducement Stock Incentive Plan.
Options have a ten-year term and vest over four years, while RSUs vest in four equal annual installments, all subject to continued service.
Dyne Therapeutics (Nasdaq:DYN) expanded its non-dilutive senior secured term loan facility with Hercules Capital to provide up to $400 million in total borrowing capacity.
The amendment adds $125 million of potential funding, with $50 million funded at closing and up to $200 million remaining available to support DMD and DM1 programs.
Dyne Therapeutics (Nasdaq:DYN) completed enrollment of 71 participants in the registrational expansion cohort (REC) of the Phase 1/2 ACHIEVE trial of z-basivarsen (DYNE-101) for myotonic dystrophy type 1 (DM1).
Topline REC data are planned for Q1 2027, targeting a potential U.S. Accelerated Approval BLA submission in Q3 2027 and a possible U.S. launch in H1 2028, assuming Priority Review and approval. Dyne is also pursuing approval paths outside the U.S.
Dyne Therapeutics (Nasdaq:DYN) submitted a Biologics License Application to the U.S. FDA for z-rostudirsen (DYNE-251), a treatment for Duchenne muscular dystrophy amenable to exon 51 skipping. The filing seeks Accelerated Approval using dystrophin as a surrogate endpoint and proposes 20 mg/kg IV once every 4 weeks.
In the registrational expansion cohort of the DELIVER trial, z-rostudirsen produced a statistically significant increase in dystrophin with functional improvement across multiple clinical endpoints and a favorable safety profile. Dyne has requested Priority Review and, if granted and approved on the expected timeline, anticipates a potential U.S. launch in Q1 2027. The company is also advancing four additional exon-skipping candidates for DMD.
Dyne Therapeutics (Nasdaq:DYN) granted inducement equity awards to 17 new employees under Nasdaq Listing Rule 5635(c)(4).
Awards include non-statutory stock options for up to 296,500 shares and 94,100 restricted stock units, all vesting over four years under Dyne’s 2024 Inducement Stock Incentive Plan.